Researchers demonstrate a new strategy to stop the TB bacterium

Sep 18, 2013
Researchers demonstrate a new strategy to stop the TB bacterium
β-lactone 7, a small molecule that inhibits the ClpP enzyme in bacteria, may be important in development of new anti-bacterial drugs. The bacterium that causes tuberculosis cannot survive when ClpP is inhibited. Credit: Sello Lab / Brown University

To stay ahead in the race against drug-resistant infections, scientists constantly search for and exploit vulnerabilities in deadly bacteria. Now, researchers from Brown and the Massachusetts Institute of Technology have used a novel compound to exploit an Achilles' heel in the bacterium that causes tuberculosis.

In a series of , the researchers have shown that it is possible to kill Mycobacterium tuberculosis by inhibiting ClpP, a that is not targeted by any antibacterial drug on the market. The work is preliminary, but the researchers are hopeful it could point the way to to treat tuberculosis and other infections that are becoming resistant to traditional antibiotics.

"ClpP has emerged over the last decade or so as a potential drug target in bacteria because they require it to either live or to cause disease," said Jason Sello, associate professor of chemistry at Brown, who led the research. "Our findings indicate that chemical inhibition of the essential ClpP enzyme in Mycobacterium tuberculosis is a viable strategy in anti-tuberculosis drug development."

A paper describing the research has been accepted by the journal ACS Chemical Biology and published online.

The ClpP (pronounced "clip-P") enzyme is sometimes referred to as "the of the bacterial cell," Sello said. It degrades and eliminates proteins inside the cell that are misfolded, damaged, or have outlived their usefulness. While ClpP is dispensable in most bacteria, previous research has shown that it is absolutely essential for the viability of M. tuberculosis. When the gene that makes the protein is knocked out of the 's genome, the organism cannot survive.

"If you can inhibit the function of the enzyme with a small molecule, then you can kill the bacterium," Sello said. "When we began our work, the validity of this approach hadn't been demonstrated."

Sello and Corey Compton, a fourth-year graduate student in his group, set out to do so in the lab. Previous research had found that small molecules called ?-lactones inhibit the ClpP protein in other bacteria, suggesting that they might do the same in M. tuberculosis.

To find out, the researchers synthesized 14 ?-lactones, each with a slightly different chemical structure. They tested the effect of those molecules against Mycobacterium smegmatis, a close relative of the tuberculosis bacterium often used in the lab because it does not cause disease. Of the 14 molecules, four were shown to kill M. smegmatis in petri dish cultures. To see if the compounds could also kill M. smegmatis's deadly cousin, Sello and Compton sent them to the Institute for Tuberculosis Research at the University of Illinois for further testing. There, they found that the compounds were indeed effective in killing M. tuberculosis as well. The most potent compound they identified—?-lactone 7—had a structure that was different from all other known inhibitors of ClpP. The potency of this compound is in the same range as streptomycin, a clinically used tuberculosis drug.

The next step was to confirm that the ?-lactone 7 and the other compounds were killing the bacteria by reacting with and inhibiting ClpP, as the team expected. To do that, Sello and his team marked the ?-lactones with a kind of chemical handle that allowed them to retrieve any proteins with which the molecules had reacted. By putting these tagged ?-lactones in a culture of M. smegmatis (the tuberculosis stand-in), the researchers were able to show that they did in fact bind to the two proteins that construct the ClpP enzyme.

"These results were extremely gratifying," Compton said. "The compounds not only interacted with ClpP but they did so quite selectively."

The final step was proving that the reaction between the ?-lactones and ClpP actually resulted in the inhibition of the enzyme's activity. For that, Sello turned to Robert Sauer at MIT, an expert on the ClpP enzyme. Sauer and Karl Schmitz, a postdoctoral fellow in his research group, had developed an in vitro assay in which the activity of ClpP could be measured in a test tube. Using this assay, Schmitz and Sauer found that when ClpP was treated with ?-lactones the activity of the enzyme was inhibited.

Taken together, the results suggest that molecules that inhibit ClpP could be an important addition to the drug arsenal for fighting tuberculosis.

"Our data validate ClpP as a viable, antibacterial ," said Sello. "We have a high degree of confidence that inactivating ClpP will inhibit the growth of Mycobacterium tuberculosis. In principle, a pharmaceutical company could develop new drugs by using the structure of ?-lactone 7 as a starting point or by using ClpP inhibition as a design strategy".

Explore further: Protein secrets of Ebola virus

More information: pubs.acs.org/doi/abs/10.1021/cb400577b

Related Stories

Potential new drug for tuberculosis

Aug 05, 2013

A new drug capable of inhibiting growth of Mycobacterium tuberculosis is reported this week in Nature Medicine. The findings may improve therapeutic options for the treatment of drug resistant tuberculosis (TB). ...

New compound defeats drug-resistant bacteria

Nov 28, 2011

It's no wonder that medicine's effort to combat bacterial infections is often described as an arms race. When new drugs are developed to combat infections, the bacterial target invariably comes up with a deterrent.

FDA approves first new tuberculosis in 40 years

Dec 31, 2012

The Food and Drug Administration says it has approved a Johnson & Johnson tuberculosis drug that is the first new medicine to fight the deadly infection in more than four decades.

Tuberculosis and Parkinson's disease linked by unique protein

Sep 04, 2013

A protein at the center of Parkinson's disease research now also has been found to play a key role in causing the destruction of bacteria that cause tuberculosis, according to scientists led by UC San Francisco microbiologist ...

Recommended for you

Chemical biologists find new halogenation enzyme

8 hours ago

Molecules containing carbon-halogen bonds are produced naturally across all kingdoms of life and constitute a large family of natural products with a broad range of biological activities. The presence of halogen substituents ...

Protein secrets of Ebola virus

13 hours ago

The current Ebola virus outbreak in West Africa, which has claimed more than 2000 lives, has highlighted the need for a deeper understanding of the molecular biology of the virus that could be critical in ...

Protein courtship revealed through chemist's lens

13 hours ago

Staying clear of diseases requires that the proteins in our cells cooperate with one another. But, it has been a well-guarded secret how tens of thousands of different proteins find the correct dancing partners ...

Decoding 'sweet codes' that determine protein fates

15 hours ago

We often experience difficulties in identifying the accurate shape of dynamic and fluctuating objects. This is especially the case in the nanoscale world of biomolecules. The research group lead by Professor Koichi Kato of ...

Conjecture on the lateral growth of Type I collagen fibrils

Sep 12, 2014

Whatever the origin and condition of extraction of type I collagen fibrils, in vitro as well as in vivo, the radii of their circular circular cross sections stay distributed in a range going from 50 to 100 nm for the most ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

triplehelix
1 / 5 (7) Sep 19, 2013
And then it evolves again and comes back stronger, just like it has today.

Once a strong medication is found for TB, ruthless screening and vaccinations must begin, and immigration must STOP immediately, and have Australian-esque rules.

Europe pretty much wiped out TB, to have it come back with a vengeance due to stupid parents thinking vaccines are harmful, and lax immigration(I'm not against immigration, but test them for TB and vaccination must be compulsory for entry).

The best way to deal with any disease is prevention, not cure. If we find something to hit it on the head with, let's take that brief moment in time before it evolves a loohole and prevent it recurring